版本:
中国

BRIEF-Helix Biopharma accelerates escalation of L-DOS47 dosing in the U.S. Phase I study

Nov 30 Helix Biopharma Corp

* Helix Biopharma Corp accelerates escalation of L-DOS47 dosing in the U.S. Phase I study

* Helix Biopharma - U.S. FDA has accepted accelerated escalation for L-DOS47 dosing in U.S. Phase I study up to 12g/kg in combination with pemetrexed/carboplatin Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐